scholarly journals Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics

Author(s):  
Andrea Dorst ◽  
Inga S. Shchelik ◽  
Daniel Schäfle ◽  
Peter Sander ◽  
Karl Gademann

<div><div><div><p>Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a cation-p interaction of the aromatic moiety with an arginine residue was identified. Therefore, the variation of the substituents and concurrently changing the electronic properties of the aryl moiety represents an interesting strategy in search for new fidaxomicin analogs. Herein, we report the first semisynthetic access to new fidaxomicin analogs with varying halogen substitutents via a Pd-catalyzed hydrodechlorination reaction. Subsequent iodination gave access to the first iodo-fidaxomicin derivatives, which matched or improved antibacterial properties compared to fidaxomicin against Mycobacterium tuberculosis and Staphylococcus aureus ATCC 29213.</p></div></div></div>

2020 ◽  
Author(s):  
Andrea Dorst ◽  
Inga S. Shchelik ◽  
Daniel Schäfle ◽  
Peter Sander ◽  
Karl Gademann

<div><div><div><p>Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a cation-p interaction of the aromatic moiety with an arginine residue was identified. Therefore, the variation of the substituents and concurrently changing the electronic properties of the aryl moiety represents an interesting strategy in search for new fidaxomicin analogs. Herein, we report the first semisynthetic access to new fidaxomicin analogs with varying halogen substituents via a Pd-catalyzed hydrodechlorination reaction. Subsequent iodination gave access to the first iodo-fidaxomicin derivatives, which matched or improved antibacterial properties compared to fidaxomicin against Mycobacterium tuberculosis and Staphylococcus aureus ATCC 29213.</p></div></div></div>


2020 ◽  
Author(s):  
Andrea Dorst ◽  
Inga S. Shchelik ◽  
Daniel Schäfle ◽  
Peter Sander ◽  
Karl Gademann

<div><div><div><p>Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a cation-p interaction of the aromatic moiety with an arginine residue was identified. Therefore, the variation of the substituents and concurrently changing the electronic properties of the aryl moiety represents an interesting strategy in search for new fidaxomicin analogs. Herein, we report the first semisynthetic access to new fidaxomicin analogs with varying halogen substituents via a Pd-catalyzed hydrodechlorination reaction. Subsequent iodination gave access to the first iodo-fidaxomicin derivatives, which matched or improved antibacterial properties compared to fidaxomicin against Mycobacterium tuberculosis and Staphylococcus aureus ATCC 29213.</p></div></div></div>


2006 ◽  
Vol 14 (13) ◽  
pp. 4610-4626 ◽  
Author(s):  
Ze-Qi Xu ◽  
Krzysztof Pupek ◽  
William J. Suling ◽  
Livia Enache ◽  
Michael T. Flavin

2015 ◽  
Vol 281 ◽  
pp. 1-10 ◽  
Author(s):  
Audrey Allion-Maurer ◽  
Claire Saulou-Bérion ◽  
Romain Briandet ◽  
Sandrine Zanna ◽  
Nathalie Lebleu ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Vu Van Vu ◽  
Trinh Thi Nhung ◽  
Nguyen Thi Thanh ◽  
Luu Van Chinh ◽  
Vu Dinh Tien ◽  
...  

A series of 14 new (-)-gossypol Schiff bases and hydrazones have been synthesized via an in situ procedure in high yields. Structural data showed that all target compounds exist as the enamine tautomer. Bioassays showed that several compounds exhibited cytotoxic effects against three human cancer cell lines. Compound 8a showed the greatest cytotoxic effect against hepatocellular carcinoma (HepG2), lung carcinoma (LU-1), and breast cancer (MCF-7) cell lines with IC50 values of 20.93, 13.58, and 9.40 μM, respectively. However, in an antibacterial test, compounds 8a and 8b inhibited Staphylococcus aureus and Bacillus cereus and compound 8e inhibited only Staphylococcus aureus at the same MIC values of 1024 μg/ml.


Sign in / Sign up

Export Citation Format

Share Document